APA (7th ed.) Citation

Shah, R., Buchmeier, E. L., Kopp, H., Christoph, D. C., Griesinger, F., Reck, M., . . . Thomas, M. (2025). First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study. Lung cancer, 207, . https://doi.org/10.1016/j.lungcan.2025.108702

Chicago Style (17th ed.) Citation

Shah, Rajiv, et al. "First-line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-world MesoNet Study." Lung Cancer 207 (2025). https://doi.org/10.1016/j.lungcan.2025.108702.

MLA (9th ed.) Citation

Shah, Rajiv, et al. "First-line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-world MesoNet Study." Lung Cancer, vol. 207, 2025, https://doi.org/10.1016/j.lungcan.2025.108702.